B-cell Malignancy clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Orange, California and other locations
Our lead scientists for B-cell Malignancy research studies include Catherine Coombs, MD.